

Altus Pharmaceuticals Inc.
Form 8-K
May 09, 2007

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): May 9, 2007
Altus Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

Delaware 0-51711 04-3573277

(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

125 Sidney Street, Cambridge, Massachusetts 02139

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: 617-299-2900
Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

Item 2.02 Results of Operations and Financial Condition.

Item 7.01 Regulation FD Disclosure

Item 9.01 Financial Statements and Exhibits

SIGNATURES

Exhibit Index

Ex-99.1 Press Release dated May 9, 2007

Ex-99.2 Press Release dated May 9, 2007

Table of Contents

Item 2.02 Results of Operations and Financial Condition.

On May 9, 2007, Altus Pharmaceuticals Inc. announced its financial results for the three-month period ended March 31, 2007. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure

On May 9, 2007, Altus Pharmaceuticals Inc. announced the start of its Phase III clinical trial to evaluate the efficacy and safety of ALTU-135, an oral enzyme replacement therapy for cystic fibrosis patients with pancreatic insufficiency. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.2 to this current report on Form 8-K.

The information in this Current Report on Form 8-K and the Exhibits attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibits are furnished herewith:

99.1 Press Release dated May 9, 2007

99.2 Press Release dated May 9, 2007

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Altus Pharmaceuticals Inc.

May 9, 2007

By: */s/ Jonathan I. Lieber*

Name: *Jonathan I. Lieber*

Title: *Vice President, Chief Financial
Officer and Treasurer*

Table of Contents

Exhibit Index

Exhibit No.	Description
99.1	Press Release dated May 9, 2007
99.2	Press Release dated May 9, 2007